pharmaphorum December 20, 2023
Phil Taylor

A test that can be given to patients before they are prescribed a course of opioid analgesics to check whether they are at risk of becoming dependent on the drugs has been approved by the FDA.

AutoGenomics’ AvertD test – the first of its kind to be licensed in the US – uses DNA analysis to see if a patient has a combination of genetic variants that may be associated with an elevated risk of developing opioid use disorder (OUD).

Its approval comes as the US remains in the grip of an opioid epidemic, with tens of thousands of lives being claimed every year as a result of opioid overdosing, although, there had been signs of a slowdown in deaths...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Payment Models, Provider
Related Articles:
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article